Teladoc Health, Inc. (NYSE:TDOC) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Teladoc Health, Inc. (NYSE:TDOC) have been assigned an average rating of “Hold” from the eighteen brokerages that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, twelve have issued a hold rating and five have assigned a buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $9.50.

A number of equities analysts have recently commented on TDOC shares. Evercore ISI dropped their price objective on Teladoc Health from $9.00 to $8.00 and set an “in-line” rating on the stock in a research note on Thursday, October 30th. Citigroup lowered their target price on Teladoc Health from $10.00 to $9.00 and set a “neutral” rating on the stock in a report on Friday. Barclays started coverage on Teladoc Health in a research report on Tuesday, December 9th. They issued an “equal weight” rating and a $8.50 price target on the stock. BMO Capital Markets initiated coverage on Teladoc Health in a research report on Thursday, November 13th. They issued a “market perform” rating and a $8.00 price objective for the company. Finally, Bank of America lowered their price objective on shares of Teladoc Health from $9.00 to $8.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 25th.

Insider Activity at Teladoc Health

In related news, insider Adam C. Vandervoort sold 5,720 shares of Teladoc Health stock in a transaction dated Tuesday, December 2nd. The stock was sold at an average price of $7.49, for a total transaction of $42,842.80. Following the sale, the insider directly owned 80,732 shares of the company’s stock, valued at $604,682.68. This trade represents a 6.62% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Fernando M. Rodrigues sold 4,209 shares of the business’s stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $7.48, for a total value of $31,483.32. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 33,288 shares of company stock valued at $251,684. Company insiders own 0.58% of the company’s stock.

Institutional Trading of Teladoc Health

Several institutional investors have recently modified their holdings of the company. Dimensional Fund Advisors LP raised its stake in shares of Teladoc Health by 23.8% in the third quarter. Dimensional Fund Advisors LP now owns 6,889,194 shares of the health services provider’s stock valued at $53,260,000 after purchasing an additional 1,325,106 shares in the last quarter. Allianz Asset Management GmbH boosted its stake in Teladoc Health by 189.2% during the third quarter. Allianz Asset Management GmbH now owns 1,619,391 shares of the health services provider’s stock worth $12,518,000 after buying an additional 1,059,458 shares in the last quarter. Bridgeway Capital Management LLC bought a new stake in Teladoc Health in the 2nd quarter valued at $8,729,000. Jupiter Asset Management Ltd. bought a new stake in Teladoc Health in the 3rd quarter valued at $7,576,000. Finally, Vanguard Group Inc. raised its stake in shares of Teladoc Health by 4.2% in the 3rd quarter. Vanguard Group Inc. now owns 21,910,950 shares of the health services provider’s stock valued at $169,372,000 after buying an additional 891,732 shares in the last quarter. Institutional investors and hedge funds own 76.82% of the company’s stock.

Teladoc Health Price Performance

Shares of Teladoc Health stock opened at $7.46 on Monday. The company has a current ratio of 2.70, a quick ratio of 2.60 and a debt-to-equity ratio of 0.71. The firm has a fifty day simple moving average of $7.38 and a 200-day simple moving average of $7.81. The stock has a market capitalization of $1.32 billion, a price-to-earnings ratio of -5.82 and a beta of 2.04. Teladoc Health has a 1-year low of $6.35 and a 1-year high of $15.21.

Teladoc Health (NYSE:TDOC) last posted its earnings results on Wednesday, October 29th. The health services provider reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.05. The business had revenue of $626.44 million for the quarter, compared to analyst estimates of $625.66 million. Teladoc Health had a negative net margin of 8.84% and a negative return on equity of 10.59%. Teladoc Health’s revenue was down 2.2% compared to the same quarter last year. During the same period last year, the business posted ($0.19) EPS. Teladoc Health has set its Q4 2025 guidance at -0.250–0.100 EPS. On average, sell-side analysts expect that Teladoc Health will post -1.16 earnings per share for the current year.

About Teladoc Health

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.